Clopidogrel

Generic Name: Clopidogrel

Brand Names: Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₆ClNO_₂S

CAS Number: 113665-84-2

Unique Ingredient Identifier: A74586SNO7

Background: Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,

It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.

Clopidogrel was granted FDA approval on 17 November 1997.

Indication: 1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；

2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；

3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。

Associated Conditions: Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events

Clinical Trials

Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis

Recruiting

Conditions: Ischemic Stroke
Large-Artery Atherosclerosis (Embolus/Thrombosis)

First Posted Date: 2021-04-19

Last Posted Date: 2024-06-20

Lead Sponsor: Tongji Hospital

Target Recruit Count: 1000

Registration Number: NCT04847752

Locations: 🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Statin and Dual Antiplatelet Therapy to Prevent Early Neurological Deterioration in Branch Atheromatous Disease

Phase 2

Completed

Conditions: Acute Stroke
Statin
Dual Antiplatelet Therapy

Interventions: Drug: Clopidogrel
Drug: Aspirin
Drug: Atorvastatin
Drug: Rosuvastatin

First Posted Date: 2021-04-01

Last Posted Date: 2025-03-26

Lead Sponsor: Chang Gung Memorial Hospital

Target Recruit Count: 376

Registration Number: NCT04824911

Locations: 🇨🇳
Yenchu Huang, Chiayi City, Taiwan

The Accuracy of a Novel Platelet Activity Assay in Humans on Antiplatelet Agents: Pharmacodynamics and Comparison with Light Transmission Aggregometry

Early Phase 1

Recruiting

Conditions: Platelet Activation Testing Before/after Anti-platelet Therapy
Healthy

Interventions: Drug: Clopidogrel
Drug: Aspirin

First Posted Date: 2021-03-30

Last Posted Date: 2025-01-23

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 125

Registration Number: NCT04822363

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects

Phase 1

Conditions: Acute Ischemic Stroke

Interventions: Drug: LT3001 drug product
Drug: Placebo
Drug: Dabigatran
Drug: Aspirin
Drug: Clopidogrel
Drug: Apixaban

First Posted Date: 2021-03-22

Last Posted Date: 2021-03-22

Lead Sponsor: Lumosa Therapeutics Co., Ltd.

Target Recruit Count: 64

Registration Number: NCT04809818

Locations: 🇺🇸
Lumosa Phase 1 Unit, Cypress, California, United States

Rivaroxaban or Aspirin in Patients With CHD & GD Undergoing PCI

Phase 4

Conditions: Rivaroxaban

Interventions: Drug: clopidogrel combined with rivaroxaban arm

First Posted Date: 2021-03-18

Last Posted Date: 2021-03-18

Lead Sponsor: Shenyang Northern Hospital

Target Recruit Count: 1020

Registration Number: NCT04805710

AERIAL Trial: Antiplatelet Therapy in Heart Transplantation

Phase 3

Recruiting

Conditions: Cardiac Allograft Vasculopathy
Heart Transplant

Interventions: Drug: Placebo
Drug: Clopidogrel
Drug: aspirin

First Posted Date: 2021-02-25

Last Posted Date: 2025-04-03

Lead Sponsor: Ottawa Heart Institute Research Corporation

Target Recruit Count: 135

Registration Number: NCT04770012

Locations: 🇨🇦
University of Ottawa Heart Institute, Ottawa, Ontario, Canada
🇨🇦
Toronto General Hospital UHN, Toronto, Ontario, Canada
🇨🇦
St.Pauls Hospital, Vancouver, British Columbia, Canada

Efficacy of Ticagrelor Plus Aspirin in Mild Non-cardioembolic Ischemic Stroke

Phase 3

Completed

Conditions: Ischemic Stroke
Transient Ischemic Attack

Interventions: Drug: Clopidogrel 75 mg
Drug: Ticagrelor 90mg

First Posted Date: 2021-02-04

Last Posted Date: 2023-10-19

Lead Sponsor: Mazandaran University of Medical Sciences

Target Recruit Count: 90

Registration Number: NCT04738097

Locations: 🇮🇷
Athena Sharifi Razavi, Sari, Mazandaran, Iran, Islamic Republic of
🇮🇷
Bou-Ali Sina hospital , Mazandarn University of Medical Science, Sari, Iran, Islamic Republic of

PTRG-DES Consortium

Completed

Conditions: Coronary Artery Disease
Stent Thrombosis
Clopidogrel, Poor Metabolism of
Platelet Dysfunction

Interventions: Drug: Clopidogrel Tablets

First Posted Date: 2021-02-02

Last Posted Date: 2022-03-31

Lead Sponsor: Gyeongsang National University Hospital

Target Recruit Count: 13160

Registration Number: NCT04734028

Locations: 🇰🇷
Gyeongsang National University Changwon Hospital, Changwon, Gyeongsangnam-do, Korea, Republic of

Efficacy of Clopidogrel on Incidence of Silent Brain Infarction

Phase 4

Recruiting

Conditions: Silent Brain Infarction

Interventions: Drug: Clopidogrel treatment
Drug: Aspirin treatment

First Posted Date: 2021-01-06

Last Posted Date: 2025-02-13

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 125

Registration Number: NCT04698031

Locations: 🇺🇸
Oklahoma City VA Medical Center, Oklahoma City, OK, Oklahoma City, Oklahoma, United States

Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI

Phase 4

Recruiting

Conditions: Atrial Fibrillation
Percutaneous Coronary Interventions
Antithrombotic Therapy
Acute Coronary Syndrome

Interventions: Drug: Ticagrelor
Drug: Dabigatran Etexilate
Drug: Aspirin
Drug: Clopidogrel

First Posted Date: 2021-01-05

Last Posted Date: 2021-11-04

Lead Sponsor: Medical University of Gdansk

Target Recruit Count: 2230

Registration Number: NCT04695106

Locations: 🇵🇱
Cardiac lntensive Care Unit, First Department of Cardiology, University Clinical Centre in Gdańsk, Gdańsk, Pomorskie, Poland

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy